Major Depression in 1998: Are We Providing Optimal Therapy?

Jules Angst, M.D.

Depression is a common illness associated with long duration of episodes, high rates of chronicity, relapse and recurrence, psychosocial and physical impairment, and high suicide rate. A lifetime prevalence of approximately 17% has been widely reported, and the likelihood of recurrence is more than 50%. A conceptual shift has occurred in our understanding of depression. It is now seen as a chronic medical disorder that produces as much functional limitation and morbidity as chronic diseases such as hypertension and diabetes. Predictors of chronicity include long duration of index episode, relationship difficulties, low family income, admitting research center, and inpatient hospitalization. Risk factors for recurrence include lack of self-confidence, neuroticism, previous hospital admission, loss events, and age. The aim of treatment is to induce a stable, fully asymptomatic state with full restoration of psychosocial function and to establish a long-term state of wellness. Despite effective pharmacotherapy, depressed patients are often underdiagnosed and undertreated by both psychiatrists and primary care physicians. The psychosocial and physical impairment, comorbidity, and high suicide rate associated with chronic, recurrent depression require optimal treatment strategies. The future of antidepressant treatment should focus on remission or getting the patient well and drugs that will induce and maintain long-term recovery.

The message from epidemiologic data is that a need exists for increased recognition and treatment of patients with major depressive disorders. Further, once diagnosed, there is a need for effective long-term treatment of depression. Finally, there is a need for pharmacologic treatment that provides more than just improvement in symptoms but offers the best opportunity for complete remission and for prevention of relapse and recurrence.

DEPRESSION: A CONCEPTUAL SHIFT

Epidemiologic data from a number of countries demonstrate that major depression is a chronic, recurrent condition. Between 15% and 20% of patients have symptoms that persist for at least 2 years, and often these patients do not fully recover between depressive episodes. Epidemiologic studies indicate that the likelihood an individual who has suffered one episode of depression will experience a second episode is probably greater than 40%. Furthermore, when a patient experiences a second episode of depression, the probability that he or she will develop a third episode is increased.

These high rates of relapse and recurrence are troubling since depression is associated with a substantial risk of mortality, including up to a 15% risk of death from suicide in patients with more severe forms of the disease. Indeed, in the United States, patients with major depression account for about half of all suicides, and 15% of patients hospitalized for major depression commit suicide.

Although poorly recognized, clinical depression causes greater impairment of physical and social functioning than...
many other chronic medical illnesses such as hypertension, diabetes, or arthritis. With these findings, an important conceptual shift has occurred in our understanding of depression, where depression represents a chronic and recurrent disease that often requires maintenance treatment.

**COURSE AND OUTCOME OF DEPRESSION**

Research over the past decades has documented that the course and outcome of depression are much less favorable than frequently assumed. The overall goals of treatment for major depression are the attainment of a stable, fully asymptomatic state and full restoration of psychosocial function. Thus, with effective treatment, patients should progress from response to remission and recovery, but these positive outcomes may be interrupted with periods of relapse and recurrence. A number of factors have been identified that predict a chronic outcome or an increased risk of relapse or recurrence of major depression.

**Predictors of Chronic Outcome**

A number of comparable long-term follow-up studies have documented the poor outcome from major depression. During follow-up periods of 10 to 20 years or more, up to 62% of patients were rehospitalized for depression, 11% to 34% experienced a poor outcome, and suicide was common (Table 1). Several variables have been identified as predictors of a chronic outcome from major depression in the first 2 years of follow-up. These include long duration of index episode before intake, marital status, relationship difficulties, low family income, admitting research center, and a history of nonaffective psychiatric disorders. Other predictors of longer time to recovery are secondary unipolar subtype, inpatient hospitalization at entry, and secondary or comorbid illness such as anxiety disorders or alcohol/substance abuse. Additional sociodemographic variables found to predict a lower recovery rate include older age and female gender. Of these variables, long duration of index episode is still the best predictor of time to recovery. Indeed, examination of probabilities of recovery clearly demonstrates that the longer a patient is ill, the lower the current rate of recovery (Figure 1). Other predictors of longer time to recovery are secondary unipolar subtype, inpatient hospitalization at entry, and secondary or comorbid illness such as anxiety disorders or alcohol/substance abuse. Additional sociodemographic variables found to predict a lower recovery rate include older age and female gender.

Of these variables, long duration of index episode is still the best predictor of time to recovery. Indeed, examination of probabilities of recovery clearly demonstrates that the longer a patient is ill, the lower the current rate of recovery (Figure 1). Other predictors of longer time to recovery are secondary unipolar subtype, inpatient hospitalization at entry, and secondary or comorbid illness such as anxiety disorders or alcohol/substance abuse. Additional sociodemographic variables found to predict a lower recovery rate include older age and female gender.

**Predictors of Recurrence**

Once unipolar depression develops, it has a very high probability of becoming recurrent (Figure 1). Lavori and associates reported that 13% of patients experience a recurrence 6 months after recovery from an index episode of depression. However, the cumulative probability of recurrence more than doubles at 1 year and triples at 2 years after recovery. According to this study, three quarters of patients experienced a recurrence 5 years after recovery from an index episode of depression, confirming earlier European follow-up studies of Angst and Preisig.

Although the cumulative probability of recurrence increases over time, a number of variables have some prognostic value for recurrence. A study by Surtees and Wainwright showed that relationships between psychosocial, clinical, and demographic factors and long-term outcome indicate that psychosocial factors, in particular neuroticism and a lack of self-confidence, have the greatest prognostic significance. Indeed, limited self-confidence is strongly related to the subsequent first recurrence of affective disorder. An episode of loss events and previous hospital admission are also considered risk factors for recurrence. These results reveal the heightened risk over the long term of a poor outcome for depressive disorder consequent upon measures of personality deviance and of exposure to adversity. Additional risk factors for recurrence include a history of frequent and/or multiple episodes of depression, “double depression” (i.e., major depression plus preexisting dysthymia), onset after age 60, and a long duration of individual episodes. In contrast, the diagnosis of “melancholic” features or the severity of the depressive episode has no significant effect on the recurrence of depression.

A study by Paykel et al. demonstrated that the presence of residual symptoms after partial remission impacts on the outcome of depression. Residual depression, which has been characterized as a Hamilton Rating Scale for Depression (HAM-D) score above 8, has been reported in one third of patients with major depression. Residual symptoms occur more frequently in patients with more severe illness and include anxiety, negative thought content (e.g., guilt and hopelessness), impairment of activities, anorexia, and early insomnia. The presence of residual symptoms may be a strong predictor of relapse or recurrence of depression.

Clearly, the presence of residual depression symptoms increases the risks of relapse/recurrence of depression, but...
also could be associated with an increased risk of comorbid psychiatric conditions such as anxiety disorder. This evidence of the impact of residual symptoms on patient outcomes highlights the need for antidepressant treatment that produces full recovery and remission.

**UNDERTREATMENT OF DEPRESSION**

The mortality and morbidity associated with depression emphasize the importance of identifying and adequately treating this disorder. However, despite compelling evidence that effective treatment is available, patients with depression are underdiagnosed and undertreated by both psychiatrists and primary care physicians.

Results from studies conducted in Europe and the United States clearly indicate that patients with depression consistently receive no or subtherapeutic doses of antidepressant therapy. For example, an analysis of 250 patients admitted to a major medical center for the treatment of depression revealed that as many as 31% had been given no or very low amounts of antidepressant during the first 8 weeks of care. A study of 20 patients who were chronically depressed for 2 years demonstrated that half had not been treated or received minimal treatment. In another study, 47% of patients who were experiencing a recurrent episode of depression did not receive any preventive treatment in the month prior to the next depressive episode. The inadequacy of treatment of recurrent depression was confirmed in another investigation, which showed that more than 50% of patients with recurrent depression in whom a chronic depressive disorder developed and persisted for at least 1 year were given subtherapeutic doses of medication or none at all.

These findings are especially disturbing given the difference in outcome between treated and untreated patients. Maj and colleagues followed the course of depression over 5 years in treated and untreated patients with major depression and found a significantly lower probability of remaining well in those patients who remained untreated. Further, the undertreatment of depression appears to be a widespread phenomenon in Western countries. An early finding of the European DEPRES study, comprising more than 80,000 subjects, was that one third of patients with major depression had not consulted a health care professional about their depression. Importantly, among the 69% of patients with depression or symptoms of depression who had consulted a health care professional, 41% had been prescribed drug therapy, but only 18% had received an antidepressant. The data cited in the DEPRES study are surprisingly low and tend to confirm the conclusion that depression is being undertreated.

Even when depression is treated, the duration of treatment may be inadequate. A prospective, population-based study conducted in Scotland found that both tricyclic anti-

---

*Adapted from references 23 and 24, with permission.
depressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) were given for an inadequate duration, and almost three quarters of patients received subtherapeutic doses of TCAs. Altogether, these data suggest that there is a large burden of untreated or undertreated depression.

PHARMACOTHERAPY OF DEPRESSION

Inadequate levels of antidepressant treatment have been rationalized on the basis of inadequate diagnosis, poor patient compliance, and concerns over side effects and potential overdose attempts. In addition, the preference of some clinicians for psychosocial treatments or other somatic treatments may contribute to inadequate pharmacotherapy. However, effective treatment requires continued pharmacologic management for most individuals with recurrent depression.

Indeed, provided they are given at adequate dosages for an adequate duration, antidepressants are effective treatments for depression. However, a meta-analysis of randomized, controlled trials reported that about half of inpatients receiving TCAs, SSRIs, monoamine oxidase inhibitors (MAOIs), or heterocyclics responded to treatment, as measured by at least a 50% reduction in HAM-D score (Figure 4).

CONCLUSION

Depression is one of the most common medical illnesses and a serious cause of disability to patients. As such, it is a major public health problem that is often underrecognized and undertreated. However, the realization that major depression is often both chronic and recurrent has slowly begun to change the way that this disorder is diagnosed and treated. Increasingly, the need for long-term continuation and maintenance treatment is recognized.

Nonetheless, the psychosocial and physical impairment, comorbidity, and high suicide rate associated with chronic and recurrent depression indicate a need for continued progress in developing optimal treatment strategies. Ideally, these strategies should induce full remission, maintain long-term recovery, and be effective in treating depression and comorbid disorders. The future direction of antidepressant treatment should focus on remission, or getting the patient well.

REFERENCES

12. Thornicroft G, Sartorius N. The course and outcome of depression in different cultures: 10-year follow-up of the WHO Collaborative Study on the Assessment of Depressive Disorders. Psychol Med 1993;23:1023–1032
33. MacDonald TM. Treatment of depression: prescription for success? Prim Care Psychiatry 1997;3(suppl 1):S7–S10